Patients’ Preferences for Cytoreductive Treatments in Newly Diagnosed Metastatic Prostate Cancer: The IP5-MATTER Study

作者：Martin J. Connor, Mesfin G. Genie, Tim Dudderidge, Hangjian Wu, Johanna Sukumar, Mark Beresford, Diletta Bianchini, Chee Leok Goh, Gail Horan, Pasquale F. Innominato, Vincent Khoo, Natalia Klimowska‐Nassar, Sanjeev Madaan, Stephen Mangar, Stuart McCracken, Peter Ostler, Sangeeta Paisey, Angus Robinson, Bhavan Rai, Naveed Sarwar, Narayanan Srihari, Kamal Thippu Jayaprakash, Mohini Varughese, Mathias Winkler, Hashim U. Ahmed, Verity Watson · 发表于：European Urology Oncology · 年份：2024 · DOI：10.1016/j.euo.2024.06.010 · 被引用次数：4 · 研究领域：Prostate Cancer Diagnosis and Treatment、Prostate Cancer Treatment and Research、Advanced Radiotherapy Techniques

BACKGROUND AND OBJECTIVE: Cytoreductive treatments for patients diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) confer incremental survival benefits over systemic therapy, but these may lead to added toxicity and morbidity. Our objective was to determine patients' preferences for, and trade-offs between, additional cytoreductive prostate and metastasis-directed interventions. METHODS: A prospective multicentre discrete choice experiment trial was conducted at 30 hospitals in the UK between December 3, 2020 and January 25, 2023 (NCT04590976). The individuals were eligible for inclusion if they were diagnosed with de novo synchronous mHSPC within 4 mo of commencing androgen deprivation therapy and had performance status 0-2. A discrete choice experiment instrument was developed to elicit patients' preferences for cytoreductive prostate radiotherapy, prostatectomy, prostate ablation, and stereotactic ablative body radiotherapy to metastasis. Patients chose their preferred treatment based on seven attributes. An error-component conditional logit model was used to estimate the preferences for and trade-offs between treatment attributes. KEY FINDINGS AND LIMITATIONS: A total of 352 patients were enrolled, of whom 303 completed the study. The median age was 70 yr (interquartile range [IQR] 64-76) and prostate-specific antigen was 94 ng/ml (IQR 28-370). Metastatic stages were M1a 10.9% (33/303), M1b 79.9% (242/303), and M1c 7.6% (23/303). Patie...